Method for prolonging the over survival of a cancer patient
US10668093B2 · kind B2 · utility
0Cited by
0References
6Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Mar 6, 2018 |
| Grant date | Jun 2, 2020 |
| Priority date | — |
| Expiry date | Mar 6, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a method for treating a cancer with the combination of a topoisomerase II inhibitor (TOP2 inhibitor) and a histone deacetylation inhibitor (HDACi), provides synergistic cancer cell-killing effects, and prolonged overall survival, especially when the expression of checkpoint kinase 1 (CHK-1) is low.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.